经颅磁刺激同步特定任务干预脑卒中患者上肢运动功能障碍 (rTMS)
该临床试验的目的是研究个体化在线重复经颅磁刺激(rTMS)在中风亚急性和慢性阶段增强上肢运动康复的有效性。 它还将了解个性化在线 rTMS 干预方法的安全性。 它旨在回答的主要问题是:
- rTMS 与运动训练同步是否可以改善具有诱发运动诱发电位(MEP)能力的患者的运动康复?
- 与运动训练同步的个性化 rTMS 能否改善无法诱导 MEP 的患者的运动康复?
研究人员将在初步试验中将在线 rTMS 与离线和假刺激对 MEP 患者进行比较,看看在线 rTMS 是否能缓解运动功能障碍。 并在没有 MEP 的患者中将个体化在线 rTMS 与非个体化在线 rTMS 和假手术进行比较,看看个体化在线 rTMS 是否可以在随机、双盲和对照试验中缓解运动功能障碍。
参与者将:
- 根据每个人的 MEP 状况随机分为一组;
- 接受rTMS治疗10天,每周5个工作日,共两周;
- 在整个治疗前后接受磁共振成像(MRI)和脑电图(EEG)评估;
- 治疗前一天、治疗后一天、一个月、三个月进行量表和MEP评估。
研究概览
详细说明
在初步实验中,患者被随机分为三组:在线组、离线组和假组。 如果患者能够诱导 MEP,TMS 强度将为 80% RMT;否则,TMS 强度将为 TMS 输出的 70%~80%。
在 RCT 中,没有 MEP 的患者被随机分为三组:个体化组、非个体化组和假手术组。 患者接受为期 2 周的刺激,每天进行 4 次任务。 患者将接受为期 2 周(10 天)的刺激方案,每天执行 40 项任务。 这包括 10 项基线任务测量的 1 次会话以及与 10 项运动任务同步的 3 次 5 Hz rTMS 会话。 rTMS 将应用于同侧运动皮层,每天提供约 750 个脉冲,总共 7,500 个脉冲,强度为 TMS 输出的 70~80%。
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200025
- Shanghai Ruijin Hospital, affiliated to Shanghai Jiao Tong University, School of medicine
-
-
Songjiang
-
Shanghai、Songjiang、中国
- Shanghai Yang Zhi Rehabilitation Hospital
-
-
Yangpu
-
Shanghai、Yangpu、中国
- Changhai Hospital
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
纳入标准:
- 患者首先通过神经系统检查、CT 或 MRI 扫描被诊断为中风。
- 生命体征平稳,有一定程度的上肢运动功能障碍。
- 年龄在18岁至80岁之间。
- 认知能力无明显影响,能配合各项检查和评估,MMSE评分≥20分。
- 没有严重的并发症(如肺炎、心力衰竭、尿路感染或营养不良)。
- 病史中没有属于 TMS 禁忌症的病理状况(例如,脑内有金属的患者,如动脉瘤夹、装有心脏起搏器的患者、孕妇或有癫痫发作史的患者)。
- 患者或监护人同意签署知情同意书。
排除标准:
- 患有严重心、肺、肝、肾疾病及恶性肿瘤的患者;
- 有失语症、严重认知障碍或精神疾病病史者;
- 近一个月内有癫痫发作史或近期正在服用抗癫痫药物的患者;
- 视力或听力严重障碍,无法正常沟通者;
- 患有金属植入物、起搏器、颅骨缺陷或其他妨碍接受 TMS 的情况的人。
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:在线刺激
当患者执行运动任务时,将5 Hz RTMS应用于受影响半球的主要运动皮层。
|
当患者执行运动任务时,将5 Hz RTMS应用于受影响半球的主要运动皮层。
|
|
有源比较器:离线刺激
将5 Hz RTMS应用于受影响半球的主要运动皮层后,患者执行运动任务。
|
将5 Hz RTMS应用于受影响半球的主要运动皮层后,患者执行运动任务。
|
|
假比较器:假刺激
当患者执行运动任务时,将假RTMS应用于受影响半球的主要运动皮层。
|
当患者执行运动任务时,将假RTMS应用于受影响半球的主要运动皮层。
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Mean Change in FM-UE From Baseline
大体时间:Before intervention (day0); After intervention (day15); Follow-up 1 (day45); Follow-up 2 (day105)
|
The Fugl-Meyer Assessment (FMA) is a stroke-specific, performance-based impairment index. It is designed to assess motor functioning, balance, sensation and joint functioning in patients with post-stroke hemiplegia. It is applied clinically and in research to determine disease severity, describe motor recovery, and to plan and assess treatment. The Fugl-Meyer Assessment - Upper Extremity (FMA-UE) is the upper limb motor domain includes items assessing movement, coordination, and reflex action of the shoulder, elbow, forearm, wrist, hand. It ranges from 0 (hemiplegia) to 66 points (normal motor performance). FM-UE scale was assessed by site raters who were masked to the intervention). |
Before intervention (day0); After intervention (day15); Follow-up 1 (day45); Follow-up 2 (day105)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
基线任务的平均完成时间
大体时间:干预前(第 0 周);干预中期(第一周);干预后(第 2 周)
|
基线任务的平均完成时间是指患者在每次干预前完成基线运动任务所花费的时间(秒)。
|
干预前(第 0 周);干预中期(第一周);干预后(第 2 周)
|
|
Mean Change in ARAT score from Baseline
大体时间:Before intervention (day0); After intervention (day15); Follow-up 1 (day45); Follow-up 2 (day105)
|
The Action Research Arm Test (ARAT) is a 19 item observational measure used by physical therapists and other health care professionals to assess upper extremity performance (coordination, dexterity and functioning) in stroke recovery, brain injury and multiple sclerosis populations. The ARAT was originally described by Lyle in 1981 as a modified version of the Upper Extremity Function Test and was used to examine upper limb functional recovery post damage to the cortex. ARAT score was assessed by site raters who were masked to the intervention. |
Before intervention (day0); After intervention (day15); Follow-up 1 (day45); Follow-up 2 (day105)
|
|
Mean Change in WMFT score from Baseline
大体时间:Before intervention (day0); After intervention (day15); Follow-up 1 (day45); Follow-up 2 (day105)
|
The WMFT is used to assess the upper limb motor function of patients and serves as an effective supplement to the FMA-UE. By timing single-joint movements, multi-joint movements, and functional activities, as well as evaluating movement quality and speed, it can quantitatively assess the upper limb motor ability of stroke patients. It is more sensitive to patients with mild to moderate stroke, and its grading is relatively detailed, which can sensitively reflect the subtle changes in patients' motor function during evaluation. The WMFT consists of 15 items, among which items 1-6 are simple joint movements, and items 7-15 are complex functional actions. This scale can not only evaluate impairments but also assess the effect of training on disabilities. The WMFT has good validity and reliability and can be used to evaluate the upper limb function of stroke patients. WMFT score was assessed by site raters who were masked to the intervention. |
Before intervention (day0); After intervention (day15); Follow-up 1 (day45); Follow-up 2 (day105)
|
|
Mean Change in MBI score from Baseline
大体时间:Before intervention (day0); After intervention (day15); Follow-up 1 (day45); Follow-up 2 (day105)
|
The Barthel Index for activities of daily living was introduced in 1965 by Barthel and Mahoney to be used in the assessment of the degree of assistance required by patients with stroke (other neuromuscular or musculoskeletal disorders or oncology patients) with regards to 10 items of mobility and self-care (ADL). MBI score was assessed by site raters who were masked to the intervention. |
Before intervention (day0); After intervention (day15); Follow-up 1 (day45); Follow-up 2 (day105)
|
|
Mean Change in PSQI score from Baseline
大体时间:Before intervention (day0); After intervention (day15); Follow-up 1 (day45); Follow-up 2 (day105)
|
The Pittsburgh Sleep Quality Index (PSQI) is a widely used self-report questionnaire that assesses sleep quality over a one-month time interval. The PSQI is commonly used in both clinical and research settings to evaluate various aspects of sleep. It is a valuable tool for assessing sleep quality as it captures multiple dimensions of sleep, including both subjective experiences and objective parameters. It allows researchers and healthcare providers alike to obtain a comprehensive understanding of an individual's sleep patterns and disturbances and inform treatment decisions and interventions for sleep disorders. PSQI score was assessed by site raters who were masked to the intervention). |
Before intervention (day0); After intervention (day15); Follow-up 1 (day45); Follow-up 2 (day105)
|
|
Motor Evoked Potential (MEP) - Resting Motor Threshold (RMT)
大体时间:Before intervention (day 0); In the middle of intervention (day 6); After intervention (day15); Follow-up 1 (day 45); Follow-up 2 (day105)
|
Resting motor threshold is an objective measure of cortical excitability.
Numerous studies indicate that the success of motor recovery after stroke is significantly determined by the direction and extent of cortical excitability changes.
|
Before intervention (day 0); In the middle of intervention (day 6); After intervention (day15); Follow-up 1 (day 45); Follow-up 2 (day105)
|
|
MRI changes
大体时间:Before intervention (day 0); After intervention (day15)
|
multi-modal MRI scanned, including structural MRI, resting-fMRI, task-fMRI, and DTI
|
Before intervention (day 0); After intervention (day15)
|
|
Adverse events
大体时间:Before intervention (day 0); In the middle of intervention (day 6); After intervention (day15)
|
adverse events such as headache, sleep disturbance, etc
|
Before intervention (day 0); In the middle of intervention (day 6); After intervention (day15)
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 2022361
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
IPD 共享时间框架
IPD 共享访问标准
授权专业研究人员,包括但不限于已获得所属机构数据访问许可的从事神经科学研究的研究人员,以及与本研究有合作关系并签署数据保密协议的其他医疗机构的临床医生。
他们可以访问参与者详细的临床病史,包括既往病史和治疗过程记录;神经功能评估量表数据;以及研究期间收集的成像数据,例如脑磁共振成像(MRI)结果。 但涉及参与者隐私的敏感信息,如姓名、身份证号码、联系方式等,将严格匿名处理,确保此类信息无法被获取。
他们可以通过电子邮件联系通讯作者或第一作者。
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 分析代码
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.